Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 10/20 | 0.66 |
| ▸ | FPR3 | P25089 | 9/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | HTR3A | P46098 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14006065 | 0.85 | HTR3A (0.73) | FPR2FPR3MAPTHTR3AKMT2A | |
| SCHEMBL4912085 | 0.83 | SMN1; SMN2 (0.72) | FPR2FPR3MAPTHTR3ASMN1; SMN2 | |
| SCHEMBL4910001 | 0.83 | DRD2 (0.67) | FPR2FPR3MAPTSMN1; SMN2DRD2 | |
| SCHEMBL7510422 | 0.82 | MAPT (0.67) | FPR2FPR3MAPTHTR3ASMN1; SMN2 | |
| SCHEMBL4653516 | 0.81 | HTR3A (0.67) | FPR2FPR3MAPTHTR3ASMN1; SMN2 | |
| SCHEMBL14006120 | 0.81 | HTR3A (0.60) | HTR3ADRD2DRD4NPSR1CNR1 | |
| SCHEMBL14006119 | 0.80 | CHRNA7 (0.78) | HTR3ADRD2DRD4 | |
| SCHEMBL14006121 | 0.80 | HTR3A (0.60) | MAPTHTR3ADRD2DRD4NPSR1 | |
| SCHEMBL2682619 | 0.80 | FPR2 (1.00) | FPR2FPR3 | |
| SCHEMBL14006194 | 0.79 | HTR3A (0.61) | MAPTHTR3ASMN1; SMN2DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275028-A1 | Modulators or Alpha7 Nicotinic Acetylcholine Receptors and Therapeutic Uses Thereof | SIENA BIOTECH S.P.A. (IT) | 2008-11-06 | — | — | US | disclosed |
| US-20080275028-A1 | Modulators or Alpha7 Nicotinic Acetylcholine Receptors and Therapeutic Uses Thereof | SIENA BIOTECH S.P.A. (IT) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275028-A1 | Modulators or Alpha7 Nicotinic Acetylcholine Receptors and Therapeutic Uses Thereof | CHRNA7, CHRNA5, CHRNA1 | FPR2 829/4885FPR3 772/4885MAPT 545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.